IMPACT Ethics and Regulation Core Leader, Jason Karlawish, MD, hosted a virtual conversation on the shortcomings and challenges of nomenclature in Alzheimer’s disease and related dementias and learn about the opportunities to address these challenges. He was joined by IMPACT Stakeholder Advisory Committee member, Angela Taylor, BA of the Lewy Body Dementia Association.

Karlawish and Taylor discussed questions and consideration in the field’s nomenclature including:: What’s the difference between Alzheimer’s disease and dementia? Should we still use the word dementia? Does it make sense to say that a person with MCI can progress to Alzheimer’s disease? In the term ADRD, does the second “D” stand for “disease,” “disorder,” or “dementia”?

The entire discussion can be viewed on You Tube.